In order to address the ongoing debate surrounding the
potential
link between COVID-19 and thyroid cancer, our study was specifically
designed to investigate the association between these two factors.
We acquired summary data from a genome-wide association study (GWAS)
concerning COVID-19 susceptibility and severity of COVID-19 in the
European population, with a focus on their relationship with thyroid
cancer. We applied three distinct methodologies to evaluate the causality
between COVID-19 and thyroid cancer, employing Mendelian randomization
(MR)–Egger, weighted median (WM), and inverse variance-weighted
(IVW) approaches. Furthermore, we utilized a variety of techniques
to assess pleiotropy and heterogeneity, including the MR–Egger
intercept, MR–pleiotropy residual sum and outlier method (PRESSO),
and Cochran’s
Q
test. The MR analysis revealed
associations between the susceptibility of COVID-19 and thyroid cancer
(IVW odds ratio [OR]: 2.826, 95% confidence interval [CI]: [0.842,
9.483],
P
= 0.093) as well as between the risk of
COVID-19 hospitalization and thyroid cancer (IVW OR: 1.630, 95% CI:
[1.050, 2.529],
P
= 0.029). However, the relationship
between COVID-19 and the occurrence of severe thyroid cancer cases
was less evident (IVW OR: 1.061, 95% CI: [0.575, 1.956],
P
= 0.850). Our sensitivity analyses did not reveal any signs of horizontal
pleiotropy or heterogeneity. Our MR study provided compelling evidence
supporting a causal connection between the risk of COVID-19 hospitalization
and thyroid cancer. Nevertheless, the MR results derived from genetic
data do not support a causal link between susceptibility to COVID-19
and the risk of thyroid cancer or between very severe cases of COVID-19
and the risk of thyroid cancer. These findings have significant implications
for further investigations into the impact of COVID-19 on health and
the etiology of thyroid cancer.